Ipilimumab alone is an effective treatment in melanoma [48] but when compared to the efficacy and toxicity profile of PD1 inhibitors [49, 50], there is a preference to use pembrolizumab or nivolumab as first line therapy. The gene discussed is PDCD1; the disease is melanoma.